Literature DB >> 22763991

Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort.

Felix Chua1, Alexandra M Higton, Alexandra N Colebatch, Katherine O'Reilly, Sisa Grubnic, Ioannis Vlahos, Christopher J Edwards, Patrick D W Kiely.   

Abstract

OBJECTIVE: Interstitial lung disease (ILD) is an important feature of idiopathic inflammatory myositis (IIM). Factors associated with its development and progression remain incompletely understood. The authors report ethnicity differences and lung function trends that characterize the predilection for and natural history of ILD in a group of British patients with IIM.
METHODS: A 10-year retrospective analysis of patients with IIM at two hospitals was conducted. Demographic, clinico-radiological and laboratory features of cases with and without ILD were compared. Serial pulmonary function tests, including measurements of forced vital capacity, volume and diffusing capacity for carbon monoxide, were used to identify longitudinal patterns of lung disease.
RESULTS: A total of 107 patients with IIM were identified. ILD was present in 37.4%, with non-specific interstitial pneumonia being the most common radiological pattern (75%). ILD was more common in IIM patients of Black ethnicity (OR 3.42), and in cases where ANA (OR 3.06) and anti-histidyl-tRNA synthetase (OR 3.2) antibodies were detected. In the ILD cohort, 50% deteriorated, defined as a drop in diffusing capacity of the lung for carbon monoxide by <15% or forced vital capacity <10% during the study period, occurring in all within a year of onset of ILD and significantly more frequently in those with a synchronous onset of IIM and ILD. Black ethnicity was not associated with poor lung function outcome.
CONCLUSION: In IIM, the risk of developing ILD is significantly higher in patients of Black ethnicity. Progressive lung damage occurs in an appreciable subgroup of patients with IIM-ILD, heralded by functional lung decline at 1 year despite systemic immunomodulatory treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22763991     DOI: 10.1093/rheumatology/kes167

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  9 in total

Review 1.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

2.  Myositis: Prognostic factors in 'pneumo-myositis'.

Authors:  Sonye K Danoff
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 3.  Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis.

Authors:  Patrick D W Kiely; Felix Chua
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

4.  Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias.

Authors:  Laurens J De Sadeleer; Ellen De Langhe; Nicolas Bodart; Alain Vigneron; Xavier Bossuyt; Wim A Wuyts
Journal:  Lung       Date:  2018-03-12       Impact factor: 2.584

5.  Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review.

Authors:  Andrea Aguilar-Vazquez; Efrain Chavarria-Avila; Oscar Pizano-Martinez; Alejandra Ramos-Hernandez; Lilia Andrade-Ortega; Edy-David Rubio-Arellano; Monica Vazquez-Del Mercado
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 6.  Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis.

Authors:  Li Zhang; Guoqin Wu; Di Gao; Guijian Liu; Lin Pan; Liyan Ni; Zheng Li; Qiang Wang
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

Review 7.  Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease.

Authors:  So My Koo; Song Yee Kim; Sun Mi Choi; Hyun Kyung Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2019-05-31

8.  Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases.

Authors:  Tobias Hoffmann; Peter Oelzner; Marcus Franz; Ulf Teichgräber; Diane Renz; Martin Förster; Joachim Böttcher; Claus Kroegel; P Christian Schulze; Gunter Wolf; Alexander Pfeil
Journal:  Arthritis Res Ther       Date:  2022-05-12       Impact factor: 5.606

Review 9.  A multidisciplinary approach to the diagnosis of antisynthetase syndrome.

Authors:  Matthew Wells; Sughra Alawi; Kyaing Yi Mon Thin; Harsha Gunawardena; Adrian R Brown; Anthony Edey; John D Pauling; Shaney L Barratt; Huzaifa I Adamali
Journal:  Front Med (Lausanne)       Date:  2022-09-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.